Opus Genetics (NASDAQ:IRD) & Amgen (NASDAQ:AMGN) Financial Survey

Amgen (NASDAQ:AMGN) and Opus Genetics (NASDAQ:IRD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Amgen and Opus Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3	13	13	1	2.40
Opus Genetics	1	1	15	1	2.89

Amgen presently has a consensus price target of $380.43, indicating a potential downside of 14.34%. Opus Genetics has a consensus price target of $10.69, indicating a potential upside of 132.44%. Given Opus Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Amgen.

Risk & Volatility

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Earnings & Valuation

This table compares Amgen and Opus Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75 billion	6.53	$7.71 billion	$16.09	27.60
Opus Genetics	$14.20 million	26.77	-$49.59 million	($1.35)	-3.41

Amgen has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Insider & Institutional Ownership

76.5% of Amgen shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Amgen beats Opus Genetics on 8 of the 14 factors compared between the two stocks.

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.